{ "abstract": "Background: This study aimed to characterize the expression profile of potassium inward rectifier channel subfamily J member 11 (KCNJ11) across diverse pathological subtypes of glioma based on clinical samples from our single-center cohort. We further explored the predictive value of KCNJ11 mRNA expression for overall prognosis and temozolomide chemosensitivity in glioma patients, and validated its clinical predictive efficiency.\n\nMethods: A total of 516 glioma patients treated at the Neuro-Oncology Surgery Department of Fujian Cancer Hospital between 2006.01and 2025.01 were enrolled as the discovery cohort. Complete clinical information including gender, age, pathological subtype, WHO histological grade, IDH mutation status, 1p/19q co-deletion status, survival outcome and KCNJ11 mRNA expression levels were retrospectively collected. Univariate and multivariate Cox proportional hazards regression models were constructed to screen independent prognostic biomarkers for glioma. Three independent public glioma datasets were applied for external validation: 603 glioma cases from The Cancer Genome Atlas (TCGA), 284 cases from the Repository for Molecular Brain Neoplasia Data (REMBRANDT), and 264 cases from GSE16011 dataset in NCBI Gene Expression Omnibus (GEO). Correlations between KCNJ11 mRNA expression, clinical molecular features and overall survival (OS) were verified across all validation cohorts.\n\nResults: In our single-center discovery cohort of 516 glioma patients hospitalized from 2006 to 2025, KCNJ11 mRNA expression was significantly correlated with pathological subtype, WHO grade, IDH mutation, 1p/19q co-deletion, MGMT promoter methylation and WHO 2021 molecular classification (all P<0.05). Patients with high KCNJ11 mRNA expression exhibited markedly longer median overall survival compared with those with low expression (P<0.05). Univariate Cox regression identified age, tumor recurrence, histopathological type, WHO grade, IDH mutation, 1p/19q co-deletion, MGMT methylation and KCNJ11 mRNA expression as OS-related risk factors (all P<0.05). Multivariate Cox regression demonstrated that age (HR = 1.015, 95%CI=1.005–1.025), tumor recurrence (HR = 2.357, 95%CI=1.833–3.031), WHO histological grade (HR = 2.256, 95%CI=1.542–3.301), IDH mutation (HR = 0.717, 95%CI=0.521–0.986), 1p/19q co-deletion (HR = 0.448, 95%CI=0.283–0.709), postoperative chemotherapy (HR = 0.588, 95%CI=0.418–0.826) and KCNJ11 mRNA expression (HR = 0.687, 95%CI=0.507–0.929) were independent prognostic determinants of OS. Consistent survival trends were observed in all three external validation cohorts (TCGA, REMBRANDT, GSE16011): high KCNJ11 expression consistently predicted prolonged median OS (all P<0.05).\n\nConclusion: KCNJ11 mRNA expression level in glioma tissues is inversely associated with tumor malignant progression, with lower expression detected in higher-grade, more malignant gliomas. KCNJ11 mRNA expression serves as an independent protective prognostic biomarker for glioma patients. Furthermore, elevated KCNJ11 expression predicts superior temozolomide chemosensitivity, indicating potential clinical value for individualized adjuvant chemotherapy stratification.", "abstract_shown": true, "affiliations": [ "Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fujian Branch of Fudan University Shanghai Cancer Cente", "Basic Medical College of Fujian Medical University" ], "article_type": "research article", "arxiv": null, "author_total": 8, "authors": [ { "affs": [ 0 ], "name": "Kaijia Zhou" }, { "affs": [ 1 ], "name": "Bing Zhou" }, { "affs": [ 0 ], "name": "Qiang Gu" }, { "affs": [ 0 ], "name": "Tingming Lu" }, { "affs": [ 0 ], "name": "Qingxian Ke" }, { "affs": [ 0 ], "name": "Xiaoyin Liu" }, { "affs": [ 0 ], "name": "Jin Xu" }, { "affs": [ 1 ], "name": "Xinyan Zhang" } ], "bibtex": "https://research.draconitic.com/paper/c7p5wzcfsk25h.bib", "cited_by": 0, "doi": "10.3389/fonc.2026.1949969", "fulltext_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1949969/full", "id": "c7p5wzcfsk25h", "issns": [ "2234-943X" ], "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1949969/full", "language": "en", "licence": "CC-BY-4.0", "licence_label": "CC BY 4.0", "licence_source": "article", "licence_url": "https://creativecommons.org/licenses/by/4.0/", "metadata_licence": null, "native_subjects": [ [ "lcc", "RC254-282" ], [ "openalex", "2716|Glioma Diagnosis and Treatment" ] ], "openalex": "W7223329055", "pdf_url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1949969/pdf", "pmcid": "PMC13739537", "pmid": "42996500", "published": "2026-10-23", "publisher": "Frontiers Media SA", "ris": "https://research.draconitic.com/paper/c7p5wzcfsk25h.ris", "sources": [ { "first_seen": "2026-10-30T12:20:13Z", "native_id": "10.3389/fonc.2026.1949969", "source": "crossref", "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1949969/full" }, { "first_seen": "2026-10-30T13:43:11Z", "native_id": "4328958bf9ab4dcf84c14b00eecc811e", "source": "doaj", "url": "https://doi.org/10.3389/fonc.2026.1949969" }, { "first_seen": "2026-11-09T15:20:34Z", "native_id": "MED:42996500", "source": "europepmc", "url": "https://europepmc.org/article/MED/42996500" } ], "subjects": [ { "field": "medicine", "origin": "openalex:2716|Glioma Diagnosis and Treatment", "subfield": "human-genetics" } ], "title": "Potassium inward rectifier channel subfamily J member 11 mRNA expression in glioma and its significance in predicting prognosis and chemotherapy sensitivity", "title_text": "Potassium inward rectifier channel subfamily J member 11 mRNA expression in glioma and its significance in predicting prognosis and chemotherapy sensitivity", "type": "peer-reviewed", "updated_at": "2026-11-09T15:20:34Z", "url": "https://research.draconitic.com/paper/c7p5wzcfsk25h", "venue": "Frontiers in Oncology", "versions": [] }